{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "SARS-CoV-2",
      "analytical tools",
      "pandemic",
      "preclinical models",
      "vaccine design",
      "viruses"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34645288",
  "DateCompleted": {
    "Year": "2021",
    "Month": "12",
    "Day": "03"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "11",
    "Day": "07"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "10",
        "Day": "14"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.4155/bio-2021-0096"
    ],
    "Journal": {
      "ISSN": "1757-6199",
      "JournalIssue": {
        "Volume": "13",
        "Issue": "24",
        "PubDate": {
          "Year": "2021",
          "Month": "Dec"
        }
      },
      "Title": "Bioanalysis",
      "ISOAbbreviation": "Bioanalysis"
    },
    "ArticleTitle": "Rapid development of analytical methods for evaluating pandemic vaccines: a COVID-19 perspective.",
    "Pagination": {
      "StartPage": "1805",
      "EndPage": "1826",
      "MedlinePgn": "1805-1826"
    },
    "Abstract": {
      "AbstractText": [
        "Vaccines are key in charting a path out of the COVID-19 pandemic. However, development of new vaccines is highly dependent on availability of analytical methods for their design and evaluation. This paper highlights the challenges presented in having to rapidly develop vaccine analytical tools during an ongoing pandemic, including the need to address progressive virus mutation and adaptation which can render initial assays unreliable or redundant. It also discusses the potential of new computational modeling techniques to model and analyze key viral proteins and their attributes to assist vaccine production and assay design. It then reviews the current range of analytical tools available for COVID-19 vaccine application, ranging from <i>in vitro</i> assays for immunogen characterization to assays to measure vaccine responses <i>in vivo</i>. Finally, it provides a future perspective for COVID-19 vaccine analytical tools and attempts to predict how the field might evolve over the next 5-10\u00a0years."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0002-0367-8939"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Vaxine Pty Ltd, 11 Walkley Avenue, Adelaide, 5046, Australia."
          }
        ],
        "LastName": "Baldwin",
        "ForeName": "Jeremy",
        "Initials": "J"
      },
      {
        "Identifier": [
          "0000-0002-4740-4972"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Vaxine Pty Ltd, 11 Walkley Avenue, Adelaide, 5046, Australia."
          },
          {
            "Identifier": [],
            "Affiliation": "College of Medicine & Public Health, Flinders University, Adelaide, 5042, Australia."
          }
        ],
        "LastName": "Piplani",
        "ForeName": "Sakshi",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Vaxine Pty Ltd, 11 Walkley Avenue, Adelaide, 5046, Australia."
          },
          {
            "Identifier": [],
            "Affiliation": "College of Medicine & Public Health, Flinders University, Adelaide, 5042, Australia."
          }
        ],
        "LastName": "Sakala",
        "ForeName": "Isaac G",
        "Initials": "IG"
      },
      {
        "Identifier": [
          "0000-0002-2872-8621"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Vaxine Pty Ltd, 11 Walkley Avenue, Adelaide, 5046, Australia."
          },
          {
            "Identifier": [],
            "Affiliation": "College of Medicine & Public Health, Flinders University, Adelaide, 5042, Australia."
          }
        ],
        "LastName": "Honda-Okubo",
        "ForeName": "Yoshikazu",
        "Initials": "Y"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Vaxine Pty Ltd, 11 Walkley Avenue, Adelaide, 5046, Australia."
          },
          {
            "Identifier": [],
            "Affiliation": "College of Medicine & Public Health, Flinders University, Adelaide, 5042, Australia."
          }
        ],
        "LastName": "Li",
        "ForeName": "Lei",
        "Initials": "L"
      },
      {
        "Identifier": [
          "0000-0002-1580-5245"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Vaxine Pty Ltd, 11 Walkley Avenue, Adelaide, 5046, Australia."
          },
          {
            "Identifier": [],
            "Affiliation": "College of Medicine & Public Health, Flinders University, Adelaide, 5042, Australia."
          }
        ],
        "LastName": "Petrovsky",
        "ForeName": "Nikolai",
        "Initials": "N"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Bioanalysis",
    "NlmUniqueID": "101512484",
    "ISSNLinking": "1757-6180"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "COVID-19 Vaccines"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "epidemiology",
        "prevention & control",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "COVID-19 Vaccines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Pandemics"
    },
    {
      "QualifierName": [
        "isolation & purification"
      ],
      "DescriptorName": "SARS-CoV-2"
    }
  ],
  "CoiStatement": "\n<b>Financial & competing interests disclosure</b>\n. J Baldwin, Y Honda-Okubo, L Li, IG Sakala, S Piplani and N Petrovsky are affiliated with Vaxine Pty Ltd which holds the rights to Covax-19\u2122 vaccine and Advax adjuvants. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript."
}